Taysha Gene Therapies, Inc. announced that it has entered into agreement for a private placement of common shares share for proceeds of $80,000,000 on October 21, 2022. The transaction will include participation from Astellas Pharma Inc. for 15% stake and Audentes Therapeutics, Inc. for 7,266,342 shares for proceeds of $30,009,992.46. The securities are subject to Regulation D.
Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |